This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Onyx Is Hot on Amgen Bid

Stocks in this article: ONXX AMGN PFE

NEW YORK ( TheStreet) -- The hottest stock on the board today is Onyx Pharmaceuticals (ONXX).

On Friday it closed at $86.82. Then it rejected a $120/share offer from Amgen (AMGN). It opened today at over $131.

All the small speculators who follow merger and acquisition rumors the way others follow Los Angeles Dodgers slugger Yasiel Puig now have a new favorite.

Onyx originally created sorafanib, sold as Nexavar, alongside Bayer, to treat advanced forms of kidney cancer. It was later found to work on advanced liver cancer and is now getting positive results with advanced thyroid cancer, according to a press release the two companies issued today.

While Bayer was forced to license production to India last year, as Reuters reported, bringing costs there down from $5,500/month to $175, that doesn't seem to be a concern.

Amgen got the bidding started over the weekend with an unsolicited offer of $120/share, valuing the company at close to $9 billion. (It was just south of $5 billion just last week.) Onyx CEO N. Anthony Coles turned the Amgen offer down at a meeting Friday, and the race was on.

Analysts are now bidding up the company's price since they don't have to pay it. Prices of $148/share, $150/share and nearly $180/share were all tossed out to Forbes.

The idea is that Onyx' costs are declining, that its sales effort can be pushed onto a larger company and that a second cancer drug called Kyprolis, or carfilzomib, which is presently seeking Food and Drug Administration approval, could also prove a blockbuster.

There's also value seen in CEO Coles, who joined the company in 2008. At 52, he's seen as the kind of "big thinker" who might look very good running a bigger company, and the pharmaceutical industry is always looking for talent.

The next step in all this is for the bears to start making a case. There are going to be concerns expressed about the cardiac risks of Kyprolis, and about the Indian patent case that cut the costs on Nexavar. Potential bidders including Pfizer (PFE) and Bayer are going to act like poker players sensing a bluff, going quiet and coy in an effort to reduce speculation.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,561.89 +205.02 1.18%
S&P 500 2,037.81 +24.92 1.24%
NASDAQ 4,709.2010 +64.8890 1.40%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs